Trypanosome-induced Interferon-γ production in whole blood stimulation assays is associated with latent Trypanosoma brucei gambiense infections

Microbes and Infection

Volumn 18, Issue 6, 2016, Pages 436-440

  Ilboudo, Hamidou ^a   Jamonneau, Vincent ^a,b   Koffi, Mathurin ^c   Kaboré, Jacques ^a,d   Amoussa, Roukiyath ^e   Holzmuller, Philippe ^f   Garcia, André ^e   Bucheton, Bruno ^b,g   Courtin, David ^e,h,i  

^a Centre International de Recherche Developpement sur lElevage en zone Subhumide Bobo Dioulasso   (Burkina Faso)

^b Institut de recherche pour le développement   (France)

^c Univ Jean Lorougnon Guédé   (Côte d’Ivoire)

^d Université Nazi Boni   (Burkina Faso)

^e Centre d'etude et de recherche sur le paludisme associe a la grossesse et a l'enfance (Cerpage)   (Benin)

^f CIRAD   (France)

^g Programme National de Lutte contre la Trypanosomose Humaine Africaine   (Guinea)

^h INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

ⁱ Faculté des Sciences Pharmaceutiques et Biologiques   (France)

Author keywords

Cytokines; Human African trypanosomiasis; IFN ; Trypanotolerance; Whole blood stimulation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VARIANT SURFACE GLYCOPROTEIN;

ADAPTIVE IMMUNITY; AFRICAN TRYPANOSOMIASIS; ANTIBODY TITER; ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; TRYPANOSOMA; WHOLE BLOOD STIMULATION ASSAY; IMMUNOLOGY; MONONUCLEAR CELL; SECRETION (PROCESS); TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 84961793430     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2016.03.002     Document Type: Article

References (17)

1. [1] WHO, Control and Surveillance of Human African Trypanosomiasis., 2013, WHO, Geneva Technical Report Series 984.
2. [2] Franco, J.R., Simarro, P.P., Diarra, A., Ruiz-Postigo, J.A., Jannin, J.G., The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology 141 (2014), 748–760.
3. [3] Bucheton, B., MacLeod, A., Jamonneau, V., Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol 33 (2011), 438–447.
4. [4] Jamonneau, V., Ilboudo, H., Kabore, J., Kaba, D., Koffi, M., Solano, P., et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis, 6, 2012, e1691.
5. [5] Sudarshi, D., Lawrence, S., Pickrell, W.O., Eligar, V., Walters, R., Quaderi, S., et al. Human African trypanosomiasis presenting at least 29 years after infection–what can this teach us about the pathogenesis and control of this neglected tropical disease?. PLoS Negl Trop Dis, 8, 2014, e3349.
6. [6] Ilboudo, H., Jamonneau, V., Camara, M., Camara, O., Dama, E., Leno, M., et al. Diversity of response to Trypanosoma brucei gambiense infections in the Forecariah mangrove focus (Guinea): perspectives for a better control of sleeping sickness. Microbes Infect 13 (2011), 943–952.
7. [7] Garcia, A., Jamonneau, V., Magnus, E., Laveissiere, C., Lejon, V., N'Guessan, P., et al. Follow-up of Card Agglutination Trypanosomiasis Test (CATT) positive but apparently aparasitaemic individuals in Cote d'Ivoire: evidence for a complex and heterogeneous population. Trop Med Int Health 5 (2000), 786–793.
8. [8] Ilboudo, H., Bras-Goncalves, R., Camara, M., Flori, L., Camara, O., Sakande, H., et al. Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFalpha are associated with subsequent disease development. PLoS Pathog, 10, 2014, e1004469.
9. [9] Van Meirvenne, N., Magnus, E., Buscher, P., Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop 60 (1995), 189–199.
10. [10] Jamonneau, V., Bucheton, B., Kabore, J., Ilboudo, H., Camara, O., Courtin, F., et al. Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa. PLoS Negl Trop Dis, 4, 2010, e917.
11. [11] Hertz, C.J., Filutowicz, H., Mansfield, J.M., Resistance to the African trypanosomes is IFN-gamma dependent. J Immunol 161 (1998), 6775–6783.
12. [12] Boda, C., Courtioux, B., Roques, P., Pervieux, L., Vatunga, G., Josenando, T., et al. Immunophenotypic lymphocyte profiles in human African trypanosomiasis. PLoS One, 4, 2009, e6184.
13. [13] Liu, G., Sun, D., Wu, H., Zhang, M., Huan, H., Xu, J., et al. Distinct contributions of CD4+ and CD8+ T cells to pathogenesis of Trypanosoma brucei infection in the context of gamma interferon and Interleukin-10. Infect Immun 83 (2015), 2785–2795.
14. [14] Liu, G., Xu, J., Wu, H., Sun, D., Zhang, X., Zhu, X., et al. IL-27 signaling is crucial for survival of mice infected with African trypanosomes via preventing lethal effects of CD4+ T cells and IFN-gamma. PLoS Pathog, 11, 2015, e1005065.
15. [15] Mansfield, J.M., Paulnock, D.M., Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol 27 (2005), 361–371.
16. [16] Lemesre, J.L., Holzmuller, P., Goncalves, R.B., Bourdoiseau, G., Hugnet, C., Cavaleyra, M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 (2007), 4223–4234.
17. [17] Abubakar, I., Stagg, H.R., Whitworth, H., Lalvani, A., How should I interpret an interferon gamma release assay result for tuberculosis infection?. Thorax 68 (2013), 298–301.